Squarepoint
ORGO icon

Squarepoint’s Organogenesis Holdings ORGO Stock Holding History

Squarepoint’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$614K Sell
252,626
-58,556
-19% -$143K ﹤0.01% 3268
2026
Q1 		$738K Buy
311,182
+176,551
+131% +$612K ﹤0.01% 3030
2025
Q4 		$697K Buy
+134,631
New +$652K ﹤0.01% 2918
2025
Q3 		– Sell
-77,459
Closed -$284K – 4805
2025
Q2 		$284K Buy
77,459
+35,051
+83% +$131K ﹤0.01% 3735
2025
Q1 		$183K Sell
42,408
-84,383
-67% -$341K ﹤0.01% 4044
2024
Q4 		$406K Buy
126,791
+44,051
+53% +$148K ﹤0.01% 3918
2024
Q3 		$237K Sell
82,740
-8,294
-9% -$23.3K ﹤0.01% 3595
2024
Q2 		$255K Buy
91,034
+40,710
+81% +$109K ﹤0.01% 3518
2024
Q1 		$143K Sell
50,324
-46,018
-48% -$156K ﹤0.01% 3718
2023
Q4 		$394K Buy
96,342
+82,210
+582% +$230K ﹤0.01% 3182
2023
Q3 		$44.9K Sell
14,132
-78,968
-85% -$251K ﹤0.01% 3646
2023
Q2 		$309K Buy
93,100
+34,174
+58% +$101K ﹤0.01% 2947
2023
Q1 		$126K Buy
58,926
+40,958
+228% +$101K ﹤0.01% 2931
2022
Q4 		$48.3K Sell
17,968
-38,824
-68% -$113K ﹤0.01% 3060
2022
Q3 		$184K Buy
+56,792
New +$257K ﹤0.01% 2705
2021
Q3 		– Sell
-37,322
Closed -$620K – 3283
2021
Q2 		$620K Sell
37,322
-23,595
-39% -$440K ﹤0.01% 1986
2021
Q1 		$1.11M Buy
+60,917
New +$825K 0.01% 1422
2020
Q4 		– Sell
-67,502
Closed -$259K – 3169
2020
Q3 		$259K Buy
67,502
+46,883
+227% +$185K ﹤0.01% 1929
2020
Q2 		$79K Sell
20,619
-60,087
-74% -$217K ﹤0.01% 2052
2020
Q1 		$261K Buy
80,706
+19,163
+31% +$82K 0.01% 1362
2019
Q4 		$296K Buy
+61,543
New +$390K ﹤0.01% 2044

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Squarepoint's ORGO Position: Q2 2026 in Review

Squarepoint reduced its Organogenesis Holdings (ORGO) stake by 19% in Q2 2026, selling an estimated $143K and leaving 252,626 shares worth $614K. The position accounts for ﹤0.01% of the portfolio, ranked #3268.

Squarepoint first reported a position in ORGO in Q4 2019 and has held it in 21 quarters since. The position peaked at $1.11M in Q1 2021. 135 funds tracked by Wall St. Rank hold ORGO as of Q2 2026.

  • Squarepoint held 252,626 shares of Organogenesis Holdings worth $614K as of Q2 2026.
  • Squarepoint sold 58,556 Organogenesis Holdings shares in Q2 2026, an estimated $143K.
  • Organogenesis Holdings made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3268 holding.
  • Squarepoint first reported a position in Organogenesis Holdings in Q4 2019 and has held it in 21 quarters since.
  • Squarepoint's Organogenesis Holdings position peaked at $1.11M in Q1 2021.
  • 135 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.